Reni Benjamin
Stock Analyst at Citizens
(1.36)
# 3,606
Out of 5,128 analysts
160
Total ratings
36.76%
Success rate
-12.78%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $5.45 | +83.49% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $6.87 | +74.67% | 15 | Oct 31, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Market Perform | n/a | $1.49 | - | 8 | Aug 4, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $75.93 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.39 | +416.80% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.42 | +135.79% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $110.57 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $8.45 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $0.64 | +523.64% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.72 | +132.56% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.28 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.81 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $18.82 | -46.87% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $4.73 | +5.71% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $9.97 | +180.84% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $7.18 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $19.01 | +110.42% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.77 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.83 | +41.34% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.75 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.47 | -15.52% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $46.47 | +29.12% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.60 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $211.14 | +49.19% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $86.19 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $259.20 | +2.24% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $4.09 | +315.65% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $15.24 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.81 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $30.34 | -60.45% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $23.14 | - | 1 | Nov 15, 2017 |
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $5.45
Upside: +83.49%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $6.87
Upside: +74.67%
Allogene Therapeutics
Aug 4, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.49
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $75.93
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.39
Upside: +416.80%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.42
Upside: +135.79%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $110.57
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.45
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.64
Upside: +523.64%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.72
Upside: +132.56%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.28
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.81
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $18.82
Upside: -46.87%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $4.73
Upside: +5.71%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $9.97
Upside: +180.84%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $7.18
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $19.01
Upside: +110.42%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.77
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.83
Upside: +41.34%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $11.75
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.47
Upside: -15.52%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $46.47
Upside: +29.12%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.60
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $211.14
Upside: +49.19%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $86.19
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $259.20
Upside: +2.24%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $4.09
Upside: +315.65%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $15.24
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.81
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $30.34
Upside: -60.45%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $23.14
Upside: -